Consolidation Pembrolizumab After Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma
Patients will be treated with pembrolizumab after concurrent chemoradiotherapy with cisplatin. Patients will be treated with up to 17 cycles (approximately 1 year) of pembrolizumab until disease progression or recurrence
Nasopharyngeal Carcinoma
DRUG: Pembrolizumab|DRUG: Placebo
3-year progression-free survival (PFS) rate, The percentage of patients who have not experienced disease progression or death from any cause within 3 years from the start of treatment., 3 years after the first date of treatment
Objective Response rate (RR), The percentage of patients who are either CR or PR within 3 years from the start of treatment., 1 year after the first date of treatment|Overall survival (OS), The duration from the first date of treatment to the date of death from any cause or follow-up, 3 years after the first date of treatment|median Progression-free survival (PFS), The time at which half of the patients in a study have experienced disease progression or death, and half have not., 3 years after the first date of treatment
Phase II multi-center, randomized controlled trial of consolidation pembrolizumab after chemoradiotherapy in locally advanced nasopharyngeal carcinoma